Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijizhuang) Co. Ltd.

Shijiazhuang Pharma. Group Zhongqi Pharmaceutical Technology Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Dongmin Shen

Lan Zhang

Yanhui Li

Li Zhang

Chunlei Li

Hanyu Yang

Caixia Wang

Ying Shi

Yi Mi

Yuxiu Ma

Yujie Chen

Qingzhi Gao

Yongfeng Li

Guorui Mi

Min Liang

Xiaozhuo Chen

Wenmin Guo

Linjing Fan

Xiaolong Feng

Zhentao Liu

Xian Xiu

Yang Guo

Chunlei Liu

Yaran Zhang

Liying Yang

Rongduan Wang

Hongwu Zhang

Jia Zheng

Zhanqi Niu

Yuqing Gao

Jinxu Wang

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase may contain sulfobutyl ether cyclodextrin and an active compound.

Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt

Provided are a quinazoline derivative, a pharmaceutical composition containing the same, a method for preparation of said derivative, and an application of same as an anti-cancer drug. 

Quinazoline derivative

The present invention relates to a liposomal pharmaceutical preparation containing a multivalent ionic drug, a process for the preparation of the liposomal pharmaceutical preparation, and a use thereof in the treatment of diseases, in which the liposome has a size of about 30-80 nm, and the phospholipid bilayer has a phospholipid with a Tm higher than body temperature, so that the phase transition temperature of the liposome is higher than the body temperature.

Liposomal pharmaceutical preparation and method for manufacturing the same

The inventive subject matter relates to the use of L-butylphthalide in the manufacturing of medicaments for the prevention and treatment of cerebral ischemia-induced disease. Cerebral ischemia of the animals or human induces cerebral infarction, neurological deficit, memory disorder, cerebral edema, cerebral apoplexy, metabolic disorder of energy, changes of cerebral blood flow, and the like. The in vivo experiments show that L-butylphthalide can effectively reduce the above-mentioned adverse symptoms induced by cerebral ischemia.

Methods of using L-butylphthalide for the prevention and treatment of cerebral ischemia disease

A liposome comprising bilayer and inner water phase is disclosed. Said inner water phase contains sulfobutyl ether cyclodextrin and active compound. Said sulfobutyl ether cyclodextrin is sulfobutyl ether &#x3b1;-cyclodextrin, sulfobutyl ether &#x3b2;-cyclodextrin, or sulfobutyl ether &#x3b3;-cyclodextrin.

The present invention relates to a novel drug delivery and release system, i.e. Self-emulsifying Drug Delivery System (SEDDS), of butylphthalide, to a preparation process thereof, and to a use thereof in a pharmaceutical formulation. The drug delivery system comprises as essential ingredients 1% to 65% of butylphthalide and 10% to 65% of a emulsifying agent, together with various excipients as required depending on the desired dosage forms. The present invention significantly increases the contact area between butylphthalide and the mucous membrane of the gastrointestinal tract, and therefore improves the absorptivity of the drug.

Butylphthalide self-emulsifying drug delivery system, its preparation and method and application

Growing community of inventors

Shijiazhuang, China

Dongmin Shen